Molecular Defects of the Disease-Causing Human Arrestin-1 C147F Mutant

Sergey A. Vishnivetskiy,1 Lori S. Sullivan,2 Sara J. Bowne,2 Stephen P. Daiger,2 Eugenia V. Gurevich,1 and Vsevolod V. Gurevich1

1Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States
2Human Genetics Center, School of Public Health, The University of Texas Health Science Center, Houston, Texas, United States

Correspondence: Vsevolod V. Gurevich, Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; vsevolod.gurevich@vanderbilt.edu.

Submitted: May 10, 2017
Accepted: December 1, 2017
Citation: Vishnivetskiy SA, Sullivan LS, Bowne SJ, Daiger SP, Gurevich EV. Molecular defects of the disease-causing human arrestin-1 C147F mutant. Invest Ophthalmol Vis Sci. 2018;59:13–20. https://doi.org/10.1167/iovs.17-22180

Purpose. The purpose of this study was to identify the molecular defect in the disease-causing human arrestin-1 C147F mutant.

Methods. The binding of wild-type (WT) human arrestin-1 and several mutants with substitutions in position 147 (including C147F, which causes dominant retinitis pigmentosa in humans) to phosphorylated and unphosphorylated light-activated rhodopsin was determined. Thermal stability of WT and mutant human arrestin-1, as well as unfolded protein response in 661W cells, were also evaluated.

Results. WT human arrestin-1 was selective for phosphorylated light-activated rhodopsin. Substitutions of Cys-147 with smaller side chain residues, Ala or Val, did not substantially affect binding selectivity, whereas residues with bulky side chains in the position 147 (Ile, Leu, and disease-causing Phe) greatly increased the binding to unphosphorylated rhodopsin. Functional survival of mutant proteins with bulky substitutions at physiological and elevated temperature was also compromised. C147F mutant induced unfolded protein response in cultured cells.

Conclusions. Bulky Phe substitution of Cys-147 in human arrestin-1 likely causes rod degeneration due to reduced stability of the protein, which induces unfolded protein response in expressing cells.

Keywords: arrestin, retinitis pigmentosa, photoreceptors, protein stability

Visual arrestin-1 was first discovered for its ability to bind light-activated phosphorylated rhodopsin (P-Rh*)1 and quench rhodopsin signaling,2 apparently due to direct competition of active rhodopsin with visual G protein transducin.3,4 The function of arrestin in the termination of rhodopsin signaling is critical: the lack of arrestin,5 the absence of rhodopsin kinase,6,7 the absence or insufficient number of phosphorylation sites in rhodopsin preclude high-affinity arrestin-1 binding11,12 as well as cause visual defects in mice and humans. However, a previously identified loss-of-function mutation in arrestin-113 is recessive, as the other perfectly normal allele is sufficient for function, in line with our earlier finding that as little as 4% of wild-type (WT) arrestin expression level is sufficient for maintaining rod health in mice.14 It is interesting that recently identified C147F mutation in the human arrestin-1 is dominant and causes retinitis pigmentosa.15 Thus, loss of function cannot explain the mechanism of action of this mutant arrestin-1. Cys147 in the human arrestin-1 is homologous to the Cys145 of the bovine protein, which in crystal structures10,17 is placed in the closely packed area in the central crest of the two-domain arrestin-1 molecule between receptor-binding “finger” loop and “139-loop.”18–22 Thus, this mutation can potentially affect at least two aspects of arrestin-1 function, rhodopsin binding and folding. Here we set out to determine the molecular defects of the C147F mutant that might underlie human disease.

Methods

Materials

Materials included [γ-32P]ATP, [14C]leucine, and [3H]leucine were from Perkin-Elmer (Waltham, MA, USA). All restriction and DNA-modifying enzymes were from New England Biolabs (Ipswich, MA, USA). Rabbit reticulocyte lysate was from Ambion (Austin, TX, USA), and SP6 RNA polymerase was prepared as described.25

Mutagenesis and Plasmid Construction

For in vitro transcription, the human arrestin-1 cDNA was subcloned into pGEM2 (Promega, Madison, WI, USA) with “idealized” 5′UTR23 between NcoI and HindIII sites, as described for the bovine11 and mouse arrestin-1.24 All mutations were introduced in the transcript construct by PCR and verified by dinodeoxy sequencing. For Escherichia coli expression, cDNA encoding WT human arrestin-1 and its C147F mutant was subcloned into pTrcHisB vector between NcoI and HindIII sites (this eliminates His6-tag so that unmodified protein is expressed), as described.25 Test expression in 5 mL bacterial culture, cell lysis, and separation of soluble protein from cell debris were performed, as described.26 In vitro transcription, translation, preparation of phosphorylated and unphosphorylated rhodopsin were performed as described recently.27,28
Molecular Defects of the Human Arrestin-1 C147F Mutant

Electrophoresis, Autoradiography, and Western Blotting

Cell-free translated protein labeled with $^{14}$C-Leu and $^3$H-Leu was subjected to SDS-PAGE in 10% polyacrylamide (PAAG) gel, which was then stained with a reagent (GelCode Blue Coomassie-based; Thermo Scientific, City State, USA), de-stained with water, and soaked in 10% 2,5-diphenyloxazole (PPO) in acetic acid. PPO was then precipitated within the gel by immersing it in water, and radioactive bands were visualized by autoradiography with X-ray film. Aliquots of the lysates of arrestin-expressing E. coli and supermutants after high-speed centrifugation of these lysates containing soluble proteins were subjected to SDS-PAGE in 10% PAAG gel and transferred to polyvinylidene fluoride (PVDF) membranes. Arrestin bands were visualized using pan-arrestin rabbit F431 primary and horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibodies, followed by incubation with reagent (WestPico ECL; Thermo Scientific) and exposure to X-ray film.

Direct binding assay was performed, as described. Briefly, 1 nM arrestin-1 (50 fmol) was incubated with 0.3 μg P-Rh* or Rh* (11 pmol, yielding final concentration of 0.22 μM) in 50 μL of 50 mM Tris-HCL, pH 7.4; 100 mM potassium acetate; 1 mM EDTA; 1 mM dithiothreitol for 5 minutes at 37°C (or other indicated temperature) under room light. Samples were cooled on ice, whereupon bound and free arrestin-1 were separated at 4°C by gel filtration on a 2-ML column of Sepharose 2B-CL. Arrestin-1 eluting with rhodopsin-containing membranes was quantified by liquid scintillation counting. Nonspecific binding, determined in samples where rhodopsin was omitted, was subtracted.

In Vitro Arrestin Stability Assay

Transfected radiolabeled arrestin-1 was incubated for 1 or 2 hours at 42°C, or for up to 24 hours at 37°C, and cooled on ice. The binding of arrestin-1 to P-Rh* in these samples was compared to that of control sample kept on ice, as described above; 1 nM arrestin-1 (50 fmol per sample) was used, as in the standard direct binding assay.

Cell Culture

Photoreceptor-derived 661W 29 cells, which are more appropriate for studies of visual arrestin-1 than most cultured cell lines, were used to express WT human arrestin-1 and its C147F mutant. These cells were originally isolated from a transgenic mouse line expressing SV40 T-antigen under controls of human interphotoreceptor retinol-binding protein promoter. The cells were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum. The cells were transfected with constructs containing the coding sequence of the human arrestin-1 or its C147F mutant in pcDNA3 using transfection reagent (Trans-Hi; FormuMax Scientific, Sunnyvale, CA, USA). Empty pcDNA3 vector was used as control. Untransfected 661W cells treated for 1 hour with 100 μM tunicamycin, which inhibits N-linked glycosylation, or 1 μM thapsigargin (30 minutes), which inhibits endoplasmic reticulum (ER) Ca2+ ATPase, were used as positive controls for ER stress and unfolded protein response (UPR). The cells were transfected 48 hours prior to harvesting or treated with thapsigargin or tunicamycin right before harvesting. The cells were lysed using 150 μL of lysis buffer (Ambion) per well of a 12-well plate. After brief sonication (10 seconds, 10% maximum power) using a sonic dismembrator (model 500; Fisher Scientific, Pittsburgh, PA, USA), the protein in the lysates was measured using Bradford method (Bio-Rad, Hercules, CA, USA). The protein was precipitated by the addition of nine volumes of methanol and pelleted by centrifugation for 10 minutes at 13,000 rpm (Eppendorf Minispin centrifuge). The pellet was washed with 1 mL 90% methanol, dried, and dissolved in SDS sample buffer (Sigma-Aldrich Corp., St. Louis, MO, USA) at 0.5 μg/μL.

Western Blotting

The protein was subjected to SDS-PAGE in 10% (GAPDH and arrestin) or 8% (GRP78/Bip) acrylamide gel and transferred to PVDF membrane. The proteins were visualized using the following primary antibodies: anti-GAPDH (loading control, mouse, 1:1000), anti-arrestin (F431 rabbit polyclonal, 1:5000), and anti-BIP (rabbit polyclonal, 1:1000 dilution; Cell Signaling, Danvers, MA, USA). Blots were incubated with primary antibodies overnight at 4°C, washed three times with TBS-0.1% Tween-20, then incubated with corresponding HRP-conjugated secondary antibodies (1:5000; Jackson Immuno-Research Laboratories, Inc., West Grove, PA, USA). The bands were developed using ECL pico reagent (Thermo Fisher Scientific) (5 minutes) and visualized by exposure to X-ray film (VWR, Radnor, PA, USA). The signal was quantified using VersaDoc with QuantityOne software (Bio-Rad).

Statistical Analysis

Statistical analysis was performed by ANOVA using analysis software (StatView SAS Institute, Cary, NC, USA).

Results and Discussion

Arrestin-1 is an elongated two-domain molecule with relatively few contacts between domains (Figs. 1A, 1B), perfectly suited for proposed global conformational change upon receptor binding, which was recently confirmed by the structure of the arrestin-1-rhodopsin complex. Cys-145 in bovine arrestin-1, homologous to Cys-147 in human protein, is not exposed; it is located between the two loops in the central crest of the receptor-binding arrestin surface (Figs. 1A, 1B), where in the bovine protein it is closely packed with several hydrophobic partners: Leu132, Val247, Tyr255, and Ile323 (Fig. 1C). Thus, the substitution of a relatively small Cys side chain with a bulky Phe could potentially lead to misfolding and/or temperature-sensitive unfolding of the protein. There are two differences between Cys and Phe: the presence of a functional SH group in the former, but not in the latter, and the size of the side chain. As the vertebrate visual arrestin-1 was not reported to undergo posttranslational modifications, where the SH group could have played a role, we focused on the size of the side chain and generated mutants containing small Ala, medium-sized Val, and bulky Leu, Ile, and Phe residues in position 147. In case of the bovine arrestin, we previously found that Ala or Val in position 143 do not significantly change functional characteristics of WT arrestin-1.

Proper folding is necessary for protein functionality. Protein yield in cell-free translation and the fraction of translated protein that remains soluble after high-speed centrifugation are good indicators of proper folding. Cell-free translation is a relatively demanding system, as the cytoplasm of rabbit reticulocytes is diluted several-fold so that the concentrations of all chaperones that assist protein folding are significantly reduced. Thus, first we compared the yields of WT and mutant forms of the human arrestin-1 in cell-free translation as well as the fraction of soluble arrestin after centrifugation at ~600,000g for 1 hour (Figs. 2A, 2B). We did not detect greater...
Molecular Defects of the Human Arrestin-1 C147F Mutant

Pathology caused by the C147F mutation in human patients. In all cases, the band with the expected molecular weight of human arrestin-1 contained >95% of radiolabeled protein (Fig. 2B), indicating that WT and mutant forms of human arrestin-1 did not undergo proteolysis.

WT visual arrestin-1 from different species (bovine, mouse, and human) successfully folds even in E. coli, which has fewer chaperones than eukaryotic cells and can be purified from expressing bacteria in large quantities. Therefore, next we compared the expression of human arrestin-1 C147F mutant with the WT human and bovine proteins in E. coli, as well as the soluble fraction of these proteins (Fig. 2C). To this end, we performed test expression in 3 mL of bacterial culture. After 4-hour induction with isopropyl β-D-thiogalactopyranoside at 30°C, the cells were pelleted and lysed following standard procedure, then cell debris along with inclusion bodies (where bacteria place misfolded or denatured proteins) and aggregates were separated from soluble proteins by centrifugation at 600,000g for 1 hour. Western blotting of the aliquots of cell lysates and supernatants with rabbit antibody F431 antibody revealed that C147F mutant expresses at a higher level than does WT human arrestin-1, but practically all of it is insoluble in contrast to WT bovine and human arrestin-1 (Fig. 2C). Thus, C147F mutant either does not fold as easily as WT protein in the absence of mammalian chaperones or readily denatures and aggregates. Only a small fraction of immunoreactive material was present as smaller molecular weight species, which were visible in all cases (Fig. 2C), suggesting that in vivo proteolysis in E. coli is not a major issue. The bands with larger molecular weight, particularly the band at the top of the resolving gel (Fig. 2C), are more prominent in case of C147F mutant, suggesting that it aggregates more than WT human arrestin-1.

As the key function of arrestin is specific binding to the active phosphorylated rhodopsin, we expressed WT and mutant human arrestin-1 with several substitutions in position 147 in cell-free translation in the presence of radioactive amino acids and determined the binding of synthesized radiolabeled proteins to purified P-Rh* in our standard in vitro binding assay. Since rhodopsin used in this assay was purified from cow eyes, we used bovine arrestin-1 as a positive control (Fig. 5). We confirmed that the bovine rhodopsin binds the human arrestin-1 essentially as well as the bovine arrestin-1. We previously found this to be the case for the mouse arrestin-1, which reflects high conservation of both rhodopsin and arrestin-1 in mammals. Although the human arrestin-1 C147F mutant demonstrated the lowest P-Rh* binding in the group (Fig. 5), it differed from WT by less than 20%. As mouse retinas expressing only 12% and even 4% of WT level of arrestin-1, whereas the concentration of arrestin-1 in rods is 1 μM arrestin-1, whereas the concentration of arrestin-1 in rods is 1 μM arrestin-1, whereas the concentration of arrestin-1 in rods is six orders of magnitude higher, exceeding 2 mM. Another critical functional characteristic of arrestin-1 is high selectivity for P-Rh*: The binding to P-Rh* exceeds the binding to unphosphorylated Rh* by ~5-fold. Therefore, next we tested Rh* binding of all forms of arrestin-1. While the binding of C147A and C147V mutants to Rh* was only marginally increased compared to WT (in agreement with our earlier results with the bovine protein), substitution of Cys-147 with bulkier Leu, Ile, and Phe increased Rh* binding more than 2-fold (Fig. 3). Two lines of evidence suggest that this loss of selectivity for the phosphorylated receptor is unlikely to cause severe retinal degeneration. First, several mammalian species with healthy retinas express the phosphorylation-independent arrestin-1 splice variant p44 that demonstrates significantly higher binding to Rh* than does full-length protein.

Note the close packing of Cys-143, suggesting that a much larger side chain of phenylalanine in this position would not fit and therefore would likely cause a shift of neighboring residues and elements containing them.

than 33% difference in the expression levels of WT and mutant forms of the human arrestin-1. The fraction of these proteins that remained soluble after centrifugation was also similar, although the fraction of the soluble C147F mutant (~75%) was lower than that of the others (85% or greater) (Fig. 2A). Still, the level of translated radiolabeled C147F mutant after centrifugation was similar to that of WT protein (Fig. 2B). These data excluded gross misfolding as the likely reason for...
Second, we previously did not detect retinal degeneration or visual impairment in mice transgenically expressing engineered phosphorylation-independent arrestin-1 mutants, at least at low to physiological levels. The dominant nature of the C147F mutant in humans is also incompatible with the damage being done by its reduced selectivity because the second allele in patients encodes WT arrestin-1. In mice coexpression of WT arrestin-1 partially protects against the damage by the enhanced mutant expressed even at high levels and fully protects against lower levels of the phosphorylation-independent mutant.

However, our structure-function studies suggest that increased Rh* binding is often associated with reduced thermal stability of the protein. Therefore, next we tested the functional integrity of WT and mutant human arrestin-1 forms at elevated temperature. To make this test rigorous, we

expression of WT human arrestin-1 was 15.9 ± 0.9 fmol/μL; after high-speed centrifugation, 13.6 ± 0.8 fmol/μL remained in the supernatant). The absolute values (before normalization) were analyzed by 1-way ANOVA with protein as a factor, using Bonferroni post hoc test with correction for multiple comparisons. *P < 0.05; **P < 0.01, as compared to WT human arrestin-1.
incubated WT human arrestin-1 and mutants at 42°C for 1 and 2 hours, and then tested specific binding to P-Rh² after incubation for 1 (60 minutes) and 2 hours (120 minutes) at 42°C (control proteins were kept on ice). The means ± SD of two independent experiments performed in duplicate are shown. The data for each time point were analyzed separately by 1-way ANOVA with protein as a factor, using Bonferroni post hoc test with correction for multiple comparisons. **P < 0.01; ***P < 0.001, as compared to WT human arrestin-1. (B) The WT human arrestin-1 and C147F mutant were incubated for 30 minutes at indicated temperatures, whereupon the binding of these arrestins to P-Rh² was measured in a standard assay. *P < 0.05; ***P < 0.001, as compared to WT human arrestin-1. (C) The WT human arrestin-1 and C147F mutant were incubated for indicated times at 37°C, and the binding of these arrestins to P-Rh² was measured in a standard assay. *P < 0.05; ***P < 0.001, as compared to WT human arrestin-1.

suggest that thermal stability of the C147F mutant is severely compromised, as compared to the WT human arrestin-1. However, physiological human temperature is slightly lower than 37°C. Therefore, we compared functional survival of the WT human arrestin-1 and C147F mutant at this temperature (Fig. 4C) and found that WT retains full functionality for at least 24 hours, whereas the ability of the C147F mutant to bind P-Rh² is significantly reduced after 8 hours and completely gone after 24 hours (Fig. 4C). Thus, the C147F mutant denatures much faster than the WT protein at physiological temperature. Accelerated denaturing appears to be the most likely reason for the photoreceptor loss caused by this mutation in humans15 as the survival of these mutants at 1 hour was 2- to 3-fold higher than that of the C147F mutant (Fig. 4A).

Accelerated loss of native folding is expected to induce UPR.55 It is interesting that this loss of functional integrity is clearly related to the size of the residue in position 147, as substitutions of Cys-147 with relatively bulky Leu or Ile also overwhelm the proteasome system and cause cell death via UPR.55 Thus any acceleration of its denaturing would likely overwhelm the proteasome system and cause cell death via UPR.55 It is interesting that this loss of functional integrity is clearly related to the size of the residue in position 147, as substitutions of Cys-147 with relatively bulky Leu or Ile also cause progressive reduction of P-Rh² binding at 42°C, although the survival of these mutants at 1 hour was 2- to 3-fold higher than that of the C147F mutant (Fig. 4A).

Accelerated loss of native folding is expected to induce UPR in expressing cells. Therefore, we tested whether this is the case using photoreceptor-derived cultured 661W cells expressing the WT human arrestin-1 or its C147F mutant (Fig. 5). As a positive control, we used 661W cells treated with 1 μM thapsigargin or 100 μM tunicamycin for 1 hour, the
Molecular Defects of the Human Arrestin-1 C147F Mutant

Molecular Defects of the Human Arrestin-1 C147F Mutant

compounds that inhibit ER Ca\(^{2+}\) ATPase or N-linked glycosylation, respectively, thereby causing ER stress and UPR. As an indicator of UPR, we chose the increase in BiP/GRP78 expression,\(^5\) which is the first step in the UPR signaling cascade.\(^5\) We found that the expression of the WT human arrestin-1 does not increase BiP over the basal (control) level, whereas the expression of the C147F mutant significantly increases BiP expression. In cells expressing the C147F mutant, BiP was almost at the level observed in cells treated with tunicamycin or thapsigargin, even though achieved expression of the C147F mutant was much lower than that of WT protein (Fig. 5). The 661W cells are of photoreceptor origin and appear to express WT mouse arrestin-1 (Fig. 5) so that coexpression of the C147F mutant modeled the situation in human photoreceptors, where this mutant is coexpressed with the WT arrestin-1. Thus, arrestin-1-C147F clearly induces UPR (Fig. 5), indicating that it either does not fold properly or has much greater propensity to unfold than the WT human arrestin-1.

The three cysteines found in the N-domain of arrestin-1 of all species, as well as in other arrestin subtypes,\(^4\) were recently shown to play an important role in arrestin transition into high-affinity rhodopsin-binding conformation.\(^5\) In particular, Cys-147 in human arrestin-1, which corresponds to Cys-143 in bovine protein, is localized in a functionally and structurally critical position between the two loops in the central crest of the receptor-binding surface (Fig. 1) that are directly involved in rhodopsin binding and maintenance of the basal conformation. The finger loop (residues 68–78 in bovine protein, corresponding to residues 72–82 in human arrestin-1) was shown to directly engage the receptor by site-directed spin labeling\(^18,20\) and crystal structure of the arrestin-1–rhodopsin complex.\(^19,36\) In fact, the peptide representing the finger loop was co-crystallized with the activated rhodopsin, where it occupies the cavity between the cytoplasmic ends of the \(\alpha\)-helices\(^7\) that appears upon rhodopsin activation.\(^60\) The Cys-143 in the bovine arrestin-1 (equivalent to Cys-147 in the human protein) is the first residue of the \(\beta\)-strand IX, right at its contact with the 139-loop, encompassing residues 121–142 in the bovine and corresponding residues 125–146 in the human protein.\(^17\) This loop was shown to move by up to 17 \(\AA\) upon rhodopsin binding,\(^20\) and several residues in this loop were found to directly engage the receptor.\(^19,36\) It is interesting that shortening this loop greatly reduces the arrestin-1 selectivity for P-Rh\(^*\) and the ability of the protein to maintain its basal conformation.\(^20,22\) Thus, destabilization of the basal conformation by the substitution of Cys-147\(^\ast\) by a much bulkier phenylalanine, observed in vitro (Fig. 4) and in cultured cells (Fig. 5), is consistent with available structural data.

**Conclusions**

Our characterization of the WT and mutant human arrestin-1 indicates that reduced protein stability underlies the pathogenesis and dominant nature of disease-causing C147F mutation in arrestin-1. Reduced stability was determined directly as accelerated loss of activity upon incubation at elevated temperature (Fig. 4), induction of UPR in cell culture (Fig. 5), as well as indirectly, as reflected in increased binding to a nonpreferred form of rhodopsin, light-activated unphosphorylated Rh\(^*\) (Fig. 3). However, considering that many species express arrestin-1 splice variant p44, which binds Rh\(^*\) much better than full-length protein without any adverse consequences, this reduction in selectivity is unlikely to be the underlying cause of photoreceptor death. Collectively, our data suggest that the most likely cause of photoreceptor death in humans carrying C147F mutation in arrestin-1 is its accelerated loss of native folding, resulting in UPR, which causes cell stress and, ultimately, photoreceptor death in patients.

**Acknowledgments**

Supported by National Institutes of Health Grants EY011500 (VVG) and EY007142 (SPD), and grants from Foundation Fighting Blindness (SPD) and the William Stamps Farish Fund (SPD).

Disclosure: S.A. Vishnevskiy, None; L.S. Sullivan, None; S.J. Bowne, None; S.P. Daiger, None; E.V. Gurevich, None; V.V. Gurevich, None

**References**

1. Kuhn H, Hall SW, Wilden U. Light-induced binding of 48-kDa protein to photoreceptor membranes is highly enhanced by phosphorylation of rhodopsin. FEBS Lett. 1984;176:473–478.

2. Wilden U, Hall SW, Kuhn H. Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. Proc Natl Acad Sci U S A. 1986;83:1174–1178.

3. Wilden U. Duration and amplitude of the light-induced cGMP hydrolysis in vertebrate photoreceptors are regulated by multiple phosphorylation of rhodopsin and by arrestin binding. Biochemistry. 1995;34:1446–1454.

4. Krupnick JG, Gurevich VV, Benovic JL. Mechanism of quenching of phototransduction. Binding competition between arrestin and transducin for phosphorhodopsin. J Biol Chem. 1997;272:18125–18131.

5. Xu J, Dodd RL, Makino CL, Simon MI, Baylor DA, Chen J. Prolonged photoreponses in transgenic mouse rods lacking arrestin. Nature. 1997;389:505–509.

6. Chen CK, Burns ME, Spencer M, et al. Abnormal photoreponses and light-induced apoptosis in rods lacking rhodopsin kinase. Proc Nat Acad Sci U S A. 1999;96:3718–3722.

7. Cideciyan AV, Zhao X, Nielsen L, Khani SC, Jacobson SG, Palczewski K. Null mutation in the rhodopsin kinase gene slows recovery kinetics of rod and cone phototransduction in man. Proc Nat Acad Sci U S A. 1998;95:328–333.

8. Chen J, Makino CL, Peachey NS, Baylor DA, Simon MI. Mechanisms of rhodopsin inactivation in vivo as revealed by a COOH-terminal truncation mutant. Science. 1995;267:374–377.

9. Apfelstedt-Sylla E, Kunisch M, Horn M, et al. Ocular findings in a family with autosomal dominant retinitis pigmentosa and a frameshift mutation altering the carboxyl terminal sequence of rhodopsin. Br J Ophthalmol. 1993;77:495–501.

10. Mendez A, Burns ME, Roca A, et al. Rapid and reproducible deactivation of rhodopsin requires multiple phosphorylation sites. Neuron. 2000;28:153–164.

11. Gurevich VV, Benovic JL. Cell-free expression of visual arrestin. Truncation mutagenesis identifies multiple domains involved in rhodopsin interaction. J Biol Chem. 1992;267:21919–21923.

12. Gurevich VV, Benovic JL. Visual arrestin interaction with rhodopsin: Sequential multisite binding ensures strict selectivity towards light-activated phosphorylated rhodopsin. J Biol Chem. 1995;268:11628–11658.

13. Fuchs S, Nakazawa M, Maw M, Tamai M, Oguchi Y, Gal A. A homozygous I-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat Genet. 1995;10:360–362.

14. Song X, Vishnevskiy SA, Seo J, Chen J, Gurevich EV, Gurevich VV. Arrestin-1 expression in rods: balancing functional performance and photoreceptor health. Neuroscience. 2011;174:37–49.
Molecular Defects of the Human Arrestin-1 C147F Mutant

15. Sullivan LS, Bowne SJ, Koboldt DC, et al. A novel dominant mutation in SAG, the arrestin-1 gene, is a common cause of retinitis pigmentosa in Hispanic families in the Southwestern United States. Invest Ophthalmol Vis Sci. 2017;58:2774-2781.

16. Granzin J, Wilden U, Choe HW, Labahn J, Krafft B, Buldt G. X-ray crystal structure of arrestin from bovine rod outer segments. Nature. 1998;391:918–921.

17. Hirsch JA, Schubert C, Gurevich VV, Sigler PB. The 2.8 A crystal structure of visual arrestin: a model for arrestin’s regulation. Cell. 1999;97:257-269.

18. Hanson SM, Francis DJ, Vishnivetskiy SA, et al. Differential interaction of spin-labeled arrestin with inactive and active phosphorhodopsin. Proc Natl Acad Sci U S A. 2006;103:4900–4905.

19. Kang Y, Zhou XE, Gao X, et al. Crystal structure of rhodopsin bound to arrestin determined by femtosecond X-ray laser. Nature. 2015;523:561–567.

20. Kim M, Vishnivetskiy SA, Van Eps N, et al. Conformation of receptor-bound visual arrestin. Proc Natl Acad Sci U S A. 2012;109:18407–18412.

21. Feuerstein SE, Pulvermuller A, Hartmann R, et al. Helix formation in arrestin accompanies recognition of photocatalyst rhodopsin. Biochemistry. 2009;48:10733–10742.

22. Vishnivetskiy SA, Baameur F, Findley KR, Gurevich VV. Critical role of the central 139-loop in stability and binding selectivity of arrestin-1. J Biol Chem. 2013;288:11741–11750.

23. Gurevich VV. Use of bacteriophage RNA polymerase in RNA synthesis. Methods Enzymol. 1996;275:382–397.

24. Vishnivetskiy SA, Chen Q, Palazzo MC, et al. Engineering visual arrestin-1 with special functional characteristics. J Biol Chem. 2013;288:11741–11750.

25. Kim M, Hanson SM, Vishnivetskiy SA, et al. Robust self-association is a common feature of mammalian visual arrestin-1. Biochemistry. 2011;50:2255–2242.

26. Vishnivetskiy SA, Zhan X, Chen Q, Iverson TM, Gurevich VV. Arrestin expression in E. coli and purification. Curr Protoc Pharmacol. 2014;67:Unit 2.11–19.

27. Vishnivetskiy SA, Raman D, Wei J, Kennedy MJ, Hurley JB, Gurevich VV. Regulation of arrestin binding by phosphorhodopsin phosphorylation level. J Biol Chem. 2007;282:32075–32083.

28. Vishnivetskiy SA, Gimenez LE, Francis DJ, et al. Few residues within an extensive binding interface drive receptor interaction and determine the specificity of arrestin proteins. J Biol Chem. 2011;286:24288–24299.

29. Al-Ubaidi MR, Font RL, Quiambao AB, et al. Bilateral retinal and brain tumors in transgenic mice expressing simian virus 40 large T antigen under control of the human interphotoreceptor retinoid-binding protein promoter. J Cell Biol. 1998;141:257–269.

30. Sullivan LS, Bowne SJ, Koboldt DC, et al. A novel dominant mutation in SAG, the arrestin-1 gene, is a common cause of retinitis pigmentosa in Hispanic families in the Southwestern United States. Invest Ophthalmol Vis Sci. 2017;58:2774-2781.

31. Milano SK, Pace HC, Kim YM, Brenner C, Benovic JL. Scaffolding functions of arrestin-2 revealed by crystal structure and mutagenesis. Biochemistry. 2002;41:3321–3328.

32. Sutton RB, Vishnivetskiy SA, Robert J, et al. Crystal structure of cone arrestin at 2.3A: evolution of receptor specificity. J Mol Biol. 2005;354:1069–1080.

33. Zhan X, Gimenez LE, Gurevich VV, Spiller BW. Crystal structure of arrestin-5 reveals the basis of the difference in receptor binding between two non-visual arrestins. J Mol Biol. 2011;406:467–478.

34. Gurevich VV, Gurevich EV. The molecular acrobatics of arrestin activation. Trends Pharmacol Sci. 2004;25:105–111.

35. Schleicher A, Kuhn H, Hofmann KP. Kinetics, binding constant, and activation energy of the 48-kDa protein- phosphorhodopsin complex by extra-metarhodopsin II. Biochemistry. 1989;28:1770–1775.

36. Zhou XE, He Y, de Waal PW, et al. Structural identification of phosphorylation codes for arrestin recruitment by G protein-coupled receptors. Cell. 2017;170:457–469.

37. Gurevich VV, Hanson SM, Song X, Vishnivetskiy SA, Gurevich EV. The functional cycle of visual arrestins in photoreceptor cells. Prog Retin Eye Res. 2011;30:405–430.

38. Vishnivetskiy SA, Francis DJ, Van Eps N, et al. The role of arrestin alpha-helix I in receptor binding. J Mol Biol. 2010;395:42–54.

39. Hanson SM, Van Eps N, Francis DJ, et al. Structure and function of the visual arrestin oligomer. EMBO J. 2007;26:1726–1736.

40. Hanson SM, Dawson ES, Francis DJ, et al. A model for the solution structure of the rod arrestin tetramer. Structure. 2008;16:924–954.

41. Gurevich VV. The selectivity of visual arrestin for light-activated phosphorhodopsin is controlled by multiple non-redundant mechanisms. J Biol Chem. 1998;273:15501–15506.

42. Gurevich VV, Benovic JL. Arrestin: mutagenesis, expression, purification, and functional characterization. Methods Enzymol. 2000;315:422–437.

43. Fernández-Sampedro MA, Invergo BM, Ramon E, Bertranpetit J, Garriga P. Functional role of positively selected amino acid substitutions in mammalian rhodopsin evolution. Sci Rep. 2016;6:21570.

44. Gurevich EV, Gurevich VV. Arrestins are ubiquitous regulators of cellular signaling pathways. Genome Biol. 2006;7:256.

45. Indrischek H, Prohaska SJ, Gurevich VV, Gurevich EV, Stadler PF. Uncovering missing pieces: duplication and deletion history of arrestins in deuterostomes. BMC Evol Biol. 2017;17:163.

46. Strissel KJ, Sokolov M, Trieu LH, Arshavsky VY. Arrestin translocation is induced at a critical threshold of visual signaling and is superstoichiometric to bleached rhodopsin. J Neurosci. 2006;26:1146–1153.

47. Palczewski K, Buczylko J, Imami NR, McDowell JH, Hargrave PA. Role of the carboxyl-terminal region of arrestin in binding to phosphorylated rhodopsin. J Biol Chem. 1991;266:15334–15339.

48. Pulvermuller A, Maretzki D, Rudnicka-Nawrot M, Smith WC, Palczewski K, Hofmann KP. Functional differences in the interaction of arrestin and its splice variant, p44, with rhodopsin. Biochemistry. 1997;36:9293–9260.

49. Smith WC, Milam AH, Dugger D, Arendt A, Hargrave PA, Palczewski K. A splice variant of arrestin. Molecular cloning and localization in bovine retina. J Biol Chem. 1994;269:15407–15410.

50. Song X, Vishnivetskiy SA, Gross OP, et al. Enhanced arrestin facilitates recovery and protects rod photoreceptors deficient in rhodopsin phosphorylation. Curr Biol. 2009;19:700–705.

51. Song X, Seo J, Baumeur F, et al. Rapid degeneration of rod photoreceptors expressing self-association-deficient arrestin-1 mutant. Cell Signal. 2013;25:2613–2624.

52. Cleghorn WM, Tsakem EL, Song X, et al. Progressive reduction of its expression in rods reveals two pools of arrestin-1 in the outer segment with different roles in photoreceptor recovery. PloS One. 2011;6:e22797.

53. Hanson SM, Gurevich EV, Vishnivetskiy SA, Ahmed MR, Song X, Gurevich VV. Each rhodopsin molecule binds its own arrestin. Proc Natl Acad Sci U S A. 2007;104:3125–3128.

54. Nikonorov SS, Brown BM, Davis JA, et al. Mouse cones require an arrestin for normal inactivation of phototransduction. Neuron. 2008;59:462–474.
55. Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. *Apoptosis*. 2006;11:5–13.
56. Mulhern ML, Madson CJ, Danford A, Ikese K, Kador PF, Shinojara T. The unfolded protein response in lens epithelial cells from galactosemic rat lenses. *Invest Ophthalmol Vis Sci*. 2006;47:3951–3959.
57. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. *Nat Rev Cancer* 2014;14:581–597.
58. Vishnivetskiy SA, Lee RJ, Zhou XE, et al. Functional role of the three conserved cysteines in the N domain of visual arrestin-1. *J Biol Chem*. 2017;292:12496–12502.
59. Szczepak M, Beyriere F, Hofmann KP, et al. Crystal structure of a common GPCR-binding interface for G protein and arrestin. *Nat Commun*. 2014;5:4801.
60. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. *Science*. 1996;274:768–770.